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Changes in the Canine plasma 
Lipidome after short- and Long-
term excess Glucocorticoid 
exposure
Nadja s. sieber-Ruckstuhl 1, Bo Burla 2, susanne spoerel 1, Florence schmid1, 
Claudio Venzin4, Amaury Cazenave-Gassiot  3, Anne K. Bendt 2, Federico torta 3, 
Markus R. Wenk 2,3 & Felicitas s. Boretti 1
Glucocorticoids (GCs) are critical regulators of metabolic control in mammals and their aberrant 
function has been linked to several pathologies. GCs are widely used in human and veterinary 
clinical practice as potent anti-inflammatory and immune suppressive agents. Dyslipidaemia is a 
frequently observed consequence of GC treatment, typified by increased lipolysis, lipid mobilization, 
liponeogenesis, and adipogenesis. Dogs with excess GC show hyperlipidaemia, hypertension, and a 
higher risk of developing type 2 diabetes mellitus, but the risk of developing atherosclerotic lesions is 
low as compared to humans. this study aimed to examine alterations in the canine plasma lipidome 
in a model of experimentally induced short-term and long-term GC excess. Both treatments led to 
significant plasma lipidome alterations, which were more pronounced after long-term excess steroid 
exposure. In particular, monohexosylceramides, phosphatidylinositols, ether phosphatidylcholines, 
acyl phosphatidylcholines, triacylglycerols and sphingosine 1-phosphates showed significant changes. 
The present study highlights the hitherto unknown effects of GCs on lipid metabolism, which will 
be important in the further elucidation of the role and function of GCs as drugs and in metabolic and 
cardiovascular diseases.
Glucocorticoids (GCs) are highly effective anti-inflammatory and immunosuppressant drugs, commonly used to 
treat acute and chronic inflammatory and immune-mediated diseases. Besides their positive therapeutic effects, 
GCs also have many metabolic side effects, which are typically more severe after high doses and chronic appli-
cations. These adverse effects include hypertension, thin and fragile skin, wound healing disturbances, osteo-
porosis, muscle atrophy, weight gain, steroid diabetes, and venous thromboembolism1–3. The clinical signs of 
chronic GC applications are summarised in iatrogenic Cushing’s syndrome (CS), where patients present with 
increased morbidity and mortality primarily due to cardiovascular, thrombotic, and metabolic complications4–6. 
CS can also arise from endogenous cortisol overproduction but both forms lead to indistinguishable clinical 
signs. Dyslipidaemia is a frequent feature in patients with CS, resulting from a GC-induced increase in lipolysis, 
lipid mobilization, liponeogenesis, and adipogenesis. Hypercholesterolemia, increased triglyceride levels, and 
alterations in HDL cholesterol and LDL/HDL ratios are also typically observed7–10. An aggressive lipid-lowering 
management is recommended to lower the cardiovascular disease (CVD) risk in these patients11.
Dogs have been used as models to study metabolic obesity, diabetes, dyslipidaemia and response to pharmaco-
logic interventions12. In dogs, treatment with GCs causes many of the side effects seen in humans, and extended 
GC therapy can induce iatrogenic CS. Dogs with endogenous or iatrogenic CS show hyperlipidaemia, hyper-
tension, and have a higher risk of developing type 2 diabetes mellitus13,14. However, CS in dogs does not appear 
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to increase the risk of developing atherosclerotic lesions15. This may be explained by difference in their lipid 
metabolism: unlike humans, dogs have very low cholesteryl ester transfer protein (CETP) activity, an enzyme 
that mediates the transport of triglycerides (TG) from LDL and VLDL to HDL2 and of cholesteryl esters from 
HDL2 to VLDL and LDL13,16,17. Dogs carry most of their plasma cholesterol on HDL particles, resulting in an 
athero-protective profile, as high HDL-cholesterol levels are associated with a low risk of CVD13,16,17.
In recent years, lipidomics has emerged as a new field involving the large-scale study of novel lipids as func-
tional elements and markers of disease18,19. Although little is known about the plasma lipidome composition in 
dogs17,20, a recent study suggests that dogs show the highest overall similarity to patients with dyslipidaemia in 
terms of their lipid profiles and responses to the statin, simvastatin17. Therefore, dogs may represent a relevant 
model to evaluate the effects of GCs on lipid metabolism. Thus, the aim of this study was to examine changes 
in the canine plasma lipidome after short-term and long-term exposure to excess GC. In the first experiment, 
healthy Beagle dogs received a long-term treatment with tetracosactide, a synthetic peptide, comprising the first 
24 amino acids of the adrenocorticotropic hormone (ACTH), which induced chronic endogenous cortisol secre-
tion (experimentally induced CS model)21. In the second experiment, dogs received a short-term treatment of a 
high-dose of prednisolone to study the acute effects of GC use.
Results
Clinical chemistry and phenotypes. Selected clinical chemistry parameters were measured before and 
after treatment to monitor the efficacy of prednisolone and tetracosactide treatments and the general health of the 
animals during the experiments (Fig. 1 and Supplementary Table S1). Short-term prednisolone treatment led to 
a decrease in serum cortisol levels in six of eight dogs (median of all dogs: −3.2-fold; Fig. 1a). However, dogs P4 
and P6 had increased cortisol levels (1.4-fold). By comparison, long-term tetracosactide treatment significantly 
increased plasma cortisol levels (median: 3.1-fold; Fig. 1b). Plasma lipase activities significantly increased after 
both treatments, with more relevant changes observed for dogs receiving tetracosactide (median prednisolone: 
1.9-fold, tetracosactide: 3.9-fold; Fig. 1c,d). Dog T3 showed a considerably higher lipase activity compared to the 
others. Plasma triglycerides (TG) were significantly increased after long-term tetracosactide treatment (median: 
2.2-fold) but not after short-term prednisolone treatment (Fig. 1e,f). Dog T6 showed a higher increase in TG 
levels compared to the other dogs after tetracosactide treatment. Neither treatment had a significant effect on 
total cholesterol levels (Fig. 1g,h). Alanine aminotransferase and alkaline phosphatase activities were significantly 
increased in all dogs after both treatments (median prednisolone: 2.2 and 1.8-fold, respectively, tetracosactide: 5.3 
and 7.3-fold, respectively; Fig. 1i-l).
To further test the efficacy of long-term tetracosactide treatment, we performed low-dose dexamethasone 
suppression (LDDS) and ACTH stimulation tests21,22. We found that all dogs were positive for both tests (see 
Supplementary Table S1). Furthermore, long-term tetracosactide treatment resulted in a significant body weight 
loss in all dogs (range: −2.1 to −4.4 kg, median: −3.0 kg, P = 0.0004; see Supplementary Table S1). The body 
weights were not recorded after short-term prednisolone treatment, as no relevant changes were expected after 
such a short treatment. All dogs showed polyuria, polydipsia and polyphagia after prednisolone treatment. After 
long-term tetracosactide, all but one (T6) dog showed polyuria and polydipsia. Muscle wasting was detected in 
all tetracosactide-treated dogs, except for dogs T1 and T6, and increased central obesity was observed for dogs T2 
and T3 (Supplementary Table S1).
pCA and clustering analyses of the full lipidomic dataset. Hierarchical clustering based on the abun-
dance of all measured lipid species (Supplementary Table S2) could clearly discriminate plasma samples taken 
before and after treatment with prednisolone and tetracosactide (Fig. 2a,b). Principal component analysis (PCA) 
based on the abundance of all measured lipid species separated the samples taken before and after treatments, 
and showed the distinct effects of long-term tetracosactide treatment, mostly evidenced by principle components 
PC 1 (Fig. 2c,d) and of short-term prednisolone treatment, evidenced by PC 3 (Fig. 2d). PCA plots obtained from 
fold changes of all quantified lipid species (Supplementary Table S3) showed a separation between prednisolone- 
and tetracosactide-treated dogs, mostly evidenced by PC 1 (Fig. 2e) and a separation between the sexes, evi-
denced by PC 3 and PC 4 (Fig. 2f).
Ceramides (Cer), Monohexosylceramides (Hex1Cer), Dihexosylceramides (Hex2Cer) and 
GM3. After short-term prednisolone treatment, only Cer d18:2/18:0 was significantly increased among the 16 
measured ceramides (2.7-fold; Fig. 3), whereas tetracosactide induced an increase in Cer d18:1/18:0 (3.3-fold). 
As an exception, dog T4 showed decreased levels in almost all other Cer species. Excluding dog T4, there was an 
increasing trend in the levels of Cer d18:1 Cer species, even though most of these changes were not statistically 
significant (see Supplementary Fig. S4 and Supplementary Table S5). Nine of the ten quantified monohexosylcer-
amides (Hex1Cer) were significantly increased after prednisolone treatment (1.7 to 2.2-fold; Fig. 3). After tetracos-
actide treatment, five Hex1Cer species were significantly increased (1.6 to 3.5-fold; Fig. 3). None of the quantified 
Hex2Cer species were significantly changed after either treatment (Fig. 3). Monosialodihexosylgangliosides 
(GM3) were the only gangliosides measured in this study. After prednisolone, GM3 d18:2/18:0 was significantly 
decreased (1.6-fold), whereas, after tetracosactide treatment, GM3 d18:1/18:0 and GM3 d18:2/18:0 were signifi-
cantly decreased (2.2 and 3.8-fold; Fig. 3).
sphingomyelins (sM). Prednisolone did not induce any significant changes in the levels of 20 measured SM 
species, except for SM 32:2 (Fig. 3). However, dog P5 showed higher, and dog P6, lower, levels in almost all SM 
species compared to the average trend in the prednisolone group. Long-term tetracosactide treatment resulted in 
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significant increases in SM 34:0 and SM 36:1 (1.7 and 2.2-fold). In particular, dogs T4 and T5 showed decreased 
levels in all other SM species, whereas the remaining dogs showed variable, non-significant changes.
Sphingosine 1-phosphate (S1P). The major plasma S1P species, S1P d16:1, S1P d18:0, S1P d18:1 and S1P 
d18:2, were all significantly increased after short-term prednisolone treatment (1.3 to 1.8-fold; Fig. 3). However, 
Figure 1. Changes in clinical plasma markers of lipid metabolism. Levels for each dog before (0 d and 0 w, 
respectively) and after (3 d and 25 w, respectively) treatment with short-term prednisolone (left) or long-
term tetracosactide (right). Values from the same dog, before and after treatment, are connected with dotted 
lines. The P values of paired two-tailed t tests comparing log-transformed values before and after treatment 
are indicated at the top of each panel. Small inserts illustrate data at a magnified scale. ALAT, alanine 
aminotransferase activity; ALP alkaline phosphatase activity; TG triglycerides.
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Figure 2. Principal component (PCA) and clustering analyses of the plasma lipidomic datasets before and after 
treatments. All plots are based on concentrations of all quantified lipid species in all plasma samples before 
and after short-term (3 days) prednisolone (dogs P1-P8) or long-term (25 weeks) tetracosactide (dogs T1-
T6) treatments. Female dogs have underlined IDs. (a,b) Heatmaps showing the full datasets with abundance 
from all quantified lipid species in the plasma samples before (empty bar) and after (filled bar) treatment with 
short-term prednisolone (A, blue) or long-term tetracosactide (B, red). Colour scale represents normalized and 
centered lipid concentrations per lipid species (in rows). Dog IDs in grey font indicate before, and blue and red, 
after prednisolone and tetracosactide treatment, respectively. (c,d) PCA showing the specific effects of long-
term tetracosactide (red squares) treatment in principal components 1 (PC 1) and of short-term prednisolone 
treatment (blue triangles) in principal components 3 (PC 3). Samples taken before treatment are indicated with 
empty symbols and samples after treatment with filled symbols. (e,f) PCA of log2-fold changes before and after 
short-term prednisolone (dogs P1-P8, blue triangles) and long-term tetracosactide (dogs T1-T6; red squares) 
treatments, respectively. PC 1 vs. PC 2 highlights distinct plasma lipidome changes between the two treatments 
(e), whereas PC 3 vs. PC 4 indicates sex-specific effects of the treatments on the plasma lipidome, separating 
female and male dogs into two clusters ((e); purple and grey ellipses, respectively).
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in dog P6, the levels of all S1P species were decreased or only slightly increased. The same dog also showed 
decreased levels of most of the measured ceramides and sphingomyelin species, all belonging to the sphingolipid 
pathway. After long-term tetracosactide treatment, only S1P d16:1 was significantly decreased (2.1-fold) in all 
dogs; none of the other S1P species showed a consistent change (Fig. 3).
ether-Lysophosphatidylcholines (LpC-o), ether-pC (pC-o), plasmalogen pCs (pC-p), ether- 
phosphatidylethanolamines (pe-o) and plasmalogen-pe (pe-p). After short-term prednisolone 
treatment, none of the measured five LPC-O, 15 PC-O, one PE-O and 9 PE-P species were changed, and only 
two of the 12 PC-Ps were significantly increased (Fig. 4). On the other hand, long-term tetracosactide treatment 
resulted in a significant decrease in four of the five LPC-O species, 13 of the 15 PC-O species and all 12 PC-P 
species (−1.5 to −3.5-fold; Fig. 4). PE-O 18:1/20:3 was also significantly decreased (2.4-fold), whereas among all 
nine PE-P species, PE-P 18:0/18:2 was significantly increased (2.1-fold) and the others were unchanged (Fig. 4).
Lysophosphatidylcholines (LpC). Among the 21 measured LPC species, LPC 19:0 was significantly 
decreased (2.2-fold) and LPC 20:5 significantly increased (4.5-fold) after short-term prednisolone treatment 
(Fig. 5a). However, in dogs P2 and P3, LPC 20:5 and also LPC 22:6 were unchanged or decreased, while in other 
six dogs they were strongly increased (5.3 to 12.8-fold, and 1.5 to 6.0-fold, respectively; see Supplementary 
Table S3). After long-term tetracosactide treatment, there was a significant decrease in the levels of five out of 11 
LPC species bearing fatty acid chain-lengths longer than 18 carbons (Fig. 5a). In contrast, there was a significant 
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Figure 3. Individual changes in plasma levels of measured plasma sphingolipid species after short-term (3 days) 
prednisolone (left panels) and long-term (25 weeks) tetracosactide (right panels) treatments. The first column (P; 
green white colour scale) indicates the FDR-adjusted P values of the paired t-test comparing log2-transformed 
concentrations before and after treatment (*P ≤ 0.05, **P ≤ 0.01). The second column (FC) indicates average fold 
changes after vs. before treatment (color scale corresponds to log2-fold changes (log2FC), the value in the fields 
to fold changes). Subsequent columns indicate log2-fold changes for the individual dogs (P1-P8 for prednisolone, 
T1-T6 for tetracosactide; female dogs are underlined) after vs. before treatment. |FC| > 4 are capped at the colour 
scale with the maximum red and blue colour. Dark grey rows (NQ) indicate lipid species that were not detectable 
or did not meet the quality control criteria in the corresponding treatment group.
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increase in LPC 20:3 (2.4-fold) and in several LPCs bearing chain lengths shorter than 19 carbons, i.e. LPC 16:0, 
17:1, LPC 18:2 and LPC 18:3 (1.5 to 1.7-fold).
phosphatidylcholines (pC). Short-term prednisolone treatment resulted in a significant decrease in 10 
of the 37 measured PC species (Fig. 5a). In comparison, long-term tetracosactide treatment led to a significant 
decrease in the concentration of 10 PC species containing ≥4 double bonds, and in a significant increase in the 
concentration of eight PC species containing ≤3 double bonds (Fig. 5a,b). The ratio between the total concen-
tration of PC species containing ≥4 and species with ≤3 double bonds was also significantly decreased (Fig. 5b).
Lyso-phosphatidylethanolamines (Lpe) and phosphatidylethanolamines (pe). Prednisolone 
treatment had no effect on any of the five measured LPE species, whereas LPE 18:2 was increased after tetracos-
actide treatment (Fig. 5a). Of the 12 PE species tested, prednisolone only significantly increased the levels of PE 
34:1 (Fig. 5a). Tetracosactide had no significant effect on the individual and total levels of the 13 measured PE 
species (Fig. 5a,b); however, there was a considerable increase in all measured PE species in samples from dog T6. 
Excluding dog T6, a possible trend in decreased levels of individual PE species with ≥4 double bonds, and a trend 
in increased levels of PE species with ≤3 double bonds can be seen (Supplementary Fig. S4 and Supplementary 
Table S6). The ratio between the total level of PE species containing ≥4 and species with ≤3 double bonds was 
significantly decreased, independently of whether dog T6 was excluded or not (Fig. 5b and Supplementary 
Fig. S4). When excluding dog T6, a significant decrease in the total level of PE species with ≥4 double bonds and 
a significant increase in the total level of PE species with ≤3 double bonds was found (Supplementary Fig. S4).
phosphatidylinositols (pI). Short-term prednisolone treatment led to a significant decrease in 11 of the 12 
quantified PI species (−1.9 to −2.8-fold; Fig. 5a). PI 38:2 was not quantified in short-term prednisolone treatment 
samples, as in this group it did not meet the analytical QC criteria. After tetracosactide treatment, a significant 
decrease in the levels of three molecular species (PI 36:4, PI 38:4, PI 38:5; 1.6 to 2.3-fold) and in the total levels of 
PIs with ≥4 double bonds was observed. PI 38:2 was significantly (3.3-fold) and the total levels of PI species with 
≤3 double bonds were non-significantly increased (Fig. 5a,b). The ratio between the total concentration of PI 
species containing ≥4 and ≤3 double bonds was also significantly decreased (Fig. 5b).
phosphatidylserines (ps). The only quantifiable PS species (PS 38:4) did not significantly change after the 
treatments (Fig. 5a).
Diacylglycerols (DG) and triacylglycerols (TG). Prednisolone treatment led to a statistically signifi-
cant decrease in only one (TG 48:3) of the 25 quantified TG species (Fig. 6). None of the six measured DGs 
were significantly changed. However, one dog (P3) showed increased levels of DG and TG species following 
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species after short-term (3 days) prednisolone (left panels) and long-term (25 weeks) tetracosactide (right 
panels) treatments. See Fig. 3 for further descriptions.
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prednisolone treatment (Fig. 6). When P3 was excluded, a significant decrease in one DG and nine TG species 
was observed (see Supplementary Fig. S4 and Table S7). Pronounced changes were observed after long-term 
tetracosactide treatment, with a significant increase in 10 of the 31 measured TGs (3.0 to 19.9-fold); other spe-
cies showed non-significant trends in increased levels (Fig. 6). For some TG species, one or two dogs (T4 and 
T5) had decreased, while the other dogs had increased levels. Among the six measured DGs species, only DG 
18:0_18:2 was significantly elevated (4.4-fold), however a trend in increased levels in three additional DG spe-
cies was observed (Fig. 6).
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Figure 5. Individual changes in plasma levels of measured plasma acyl phospholipids after short-term (3 days) 
prednisolone (left panels) and long-term (25 weeks) tetracosactide (right panels) treatments. (a) Changes in 
individual acyl phospholipid species. See Fig. 3 for further descriptions. (b) Changes in total levels of PC, PE 
and PI lipid species with either 0 to 3 (≤3, filled circles) or 4 to 8 (≥4, open circles) fatty acid double bonds 
after long-term tetracosactide treatment. Values originating from the same dog are linked by grey dashed lines; 
the red dotted lines represent averages. P values were calculated from paired two-tailed t tests comparing log-
transformed total abundances before and after treatment (shown above the points), and comparing log2FC of 
lipids with ≤3 and ≥4 double bonds, respectively (shown on the top).
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Cholesteryl esters (Ce). Short-term prednisolone exposure did not lead to any significant changes in the 17 
quantified CE species, except of CE 24:4, which was increased (2.8-fold; Fig. 6). Tetracosactide induced a signifi-
cant decrease in the levels of CE 20:4, CE 22:4 and CE 22:5 (2.3 to 2.6-fold; Fig. 6).
Discussion
Dyslipidemia is a common consequence of exposure to excess endogenous or exogenous GC. Dogs may represent 
a relevant model to study dyslipidemia and to evaluate the effects of GCs on lipid metabolism17,23. Here, we sought 
to examine how short-term and long-term GC excess alters the canine plasma lipidome.
Short-term prednisolone treatment resulted in typical clinical signs (polyuria, polydipsia and polyphagia) and 
increased serum lipase activity. The decrease in serum cortisol concentrations during prednisolone treatment is 
expected as a result of the negative feedback of the exogenously administered GC22. In two dogs, however, serum 
cortisol levels were slightly increased, which may be ascribed to the cross-reactivity of the assay with prednisolone 
that was still present in the serum22. The weight loss, the increased serum cortisol, lipase activity, and TG levels, 
and the positive adrenal function tests of the long-term tetracosactide-treated dogs are consistent with hyper-
cortisolism and the symptoms of CS. The increased serum alanine aminotransferase and alkaline phosphatase 
activities after both treatments are likely the result of GC-induced hepatopathies and dog-specific GC-induced 
over-expression of alkaline phosphatase isoforms24,25. Considering that a substantial percentage of circulating 
lipids are transported by lipoproteins synthesised in the liver, it is plausible that hepatopathy could contribute to 
plasma lipidome changes.
The treatments with short-term prednisolone and long-term tetracosactide had distinct effects on the dog 
plasma lipidomes (Fig. 2). Of note, there were variabilities among individual dogs in the responses of the clinical 
chemistry parameters and the plasma lipidome to the treatments, which cannot be attributed to the specific dog. 
Two limitations in this study were the small sample sizes of the experimental groups and the heterogeneity in 
age of the individual dogs. Despite these age differences, the body weights of the dogs were comparable and were 
indicative of fully grown dogs in all groups. The lipid profiles diverged more between individual dogs after the 
treatments, indicating individuality in the response to the treatments (Fig. 2c,d). Biological and experimental fac-
tors, such as differences in resorption, pharmacokinetics, adrenal response, and GC sensitivity may explain such 
variabilities and have been reported previously for both humans and dogs26,27. Biological variability is expected 
within dog cohorts, which are usually more heterogeneous than, for example, mice cohorts. A sex-specific 
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Figure 6. Individual changes in plasma levels of measured plasma glycerolipids and cholesteryl esters 
after short-term (3 days) prednisolone (left panels) and long-term (25 weeks) tetracosactide (right panels) 
treatments. See Fig. 3 for further descriptions.
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response to GC, affecting plasma lipids, have been observed in humans28–30. Each treatment group in our study 
included about two-thirds male and one-third female dogs. We observed sex-specific effects on the plasma lipi-
dome in both treatments; however, these effects were weaker than the effects of the treatment (Fig. 2e,f). Given 
the already small sample size, we have not further investigated which lipids contribute to these sex-specific differ-
ences. In summary, the differences in overall plasma lipid profiles induced by the treatments were larger than the 
effects of gender, age, weight, and other possible confounding factors.
The most substantial changes in a lipid class occurring in both short-term prednisolone and long-term tetra-
cosactide exposures were found for Hex1Cer levels (Fig. 3). The increased synthesis of Hex1Cer species seen 
in our study could be attributed to an increase in their precursor ceramide or could be the result of an altered 
catabolism of complex glycosphingolipids. Interestingly, no significant changes to Hex2Cer were found, which 
derives from Hex1Cer; yet, a trend towards increased ceramide synthesis was present in response to long-term 
tetracosactide treatment (Fig. 3). This corresponds to findings in mice, where a seven days exposure to the GC 
dexamethasone resulted in an increased synthesis of specific plasma ceramides31. However, Cer levels did not 
change after short-term prednisolone treatment, which may have been too short to induce the ceramide produc-
tion. After long-term tetracosactide treatment, only one ceramide species was significantly elevated, however, 
other d18:1 ceramides tended to be elevated.
A biologically important class of sphingolipids is S1P, which is implicated in various biological processes, 
including immune reactions, vascular integrity, blood coagulation, tissue growth, apoptosis and human dis-
eases32–34. After short-term prednisolone treatment, we measured an increase in the four most abundant S1P 
molecular species, which are also the most abundant in human plasma35. Vettorazzi et al. showed that dexameth-
asone treatment led to a significant increase in plasma S1P levels in mice, which they ascribed to an induction 
in the expression of sphingosine kinase 1 (SphK1), an enzyme that phosphorylates sphingosine to S1P36. It is 
possible that the short-term prednisolone treatment in our study led to an increased synthesis of S1P, which might 
be implicated in the regulation of inflammatory processes37. Long-term tetracosactide treatment significantly 
decreased the levels of the low-abundant S1P d16:1. No data is available yet in the literature on the functions of 
S1P d16:1, probably because only recently it was possible to quantify this species in plasma35. However, it has 
been shown that sphingolipids containing the d16:0 and d16:1 sphingoid bases have, compared with the more 
abundant d18-containing sphingolipids, different biophysical and biological properties and seem to be important 
in cardiac functions38,39.
The most relevant change induced by tetracosactide treatment was measured for ether-linked PCs. Long-term 
tetracosactide exposure led to a significant reduction in the plasma levels of 29 of the 32 measured ether-linked 
PC species, while short-term prednisolone did not affect this lipid class (Fig. 4). Ether-linked PCs are synthe-
sised via a distinct pathway compared to acyl PCs40. LPC-Os (also named Lyso-PAF) are the precursors for 
platelet-activating factors (PAF). Lyso-PAF and PAF are signalling molecules implicated in platelet reactivity, 
endothelial function, and various inflammatory processes41. The decreased levels of all measured Lyso-PAF 
species after long-term tetracosactide treatment—which might consequently reflect altered levels of PAF—may 
therefore influence inflammatory processes. PC-Ps are normally enriched in the polyunsaturated fatty acids 
(PUFAs) arachidonic acid (AA) and docosahexaenoic acid (DHA), which are precursors of eicosanoids and 
related compounds40. Reduced circulating PC-P levels may also affect the protective function of lipoproteins, as 
ether- and plasmalogen phospholipids can act as scavengers of reactive oxygen species40. In contrast to our results, 
most of the ether-linked PC species were unchanged in human CS patients compared to healthy individuals42. 
This may indicate either a difference between dogs and humans in the effects of GCs on this lipid class, and/or 
a difference in tetracosactide-induced hypercortisolism in contrast to endogenous hypercortisolism in humans. 
The significance and biological role of these changes in ether-linked PCs in dogs after long-term tetracosactide 
will have to be better investigated in the future. PE-Ps were not affected by the tetracosactide treatment, suggest-
ing different functions or regulations of this lipid class compared to ether-linked PCs.
Another distinct and consistent effect of short-term prednisolone treatment—besides the effects on 
Hex1Cer—concerns the PI species, which were significantly decreased (Fig. 5a). PIs are sources of arachidonic 
acid and precursors of phosphatidylinositol phosphates (PIPs), important signalling molecules in inflammatory 
processes43,44. Phosphoinositide 3-kinases (PI3K) catalyse the synthesis of PIP from PI and interact with GCs dur-
ing the innate immune response45. It will be interesting to further investigate the mechanism and physiological 
implication of these significant changes in PI levels.
After long-term tetracosactide treatment, a significantly decreased ratio between PCs, PEs and PIs with ≥4 
and species with ≤3 double bonds was observed (Fig. 5a,b). This difference is mainly caused by a decrease in 
species with ≥4 and increases in those with ≤3 double bonds (Fig. 5a,b). Others have shown that steroids and 
ACTH can inhibit Δ5- and Δ6-desaturases in the liver and adrenal glands of rats, resulting in reduced synthesis 
of 18:3n-6, 18:4n-3 and 20:4n-6 fatty acids46. GCs may therefore reduce the synthesis of PUFA-containing phos-
pholipids and hence lower the availability of the precursor pool for eicosanoids, important factors in inflamma-
tory processes47,48. In human patients with CS, plasma levels of PC 38:3, PC 38:4, and PC 40:4 were all reduced as 
compared with healthy subjects42. In our study, however, PC 38:3 was significantly increased. In human plasma, 
PC 38:3 species mainly consists of PC 18:0/20:349,50. Interestingly, LPC 20:3 was also strongly increased. A more 
detailed analysis of the fatty acid components will be helpful in future to better understand the effects of excess 
GC on the fatty acid metabolism.
After short-term prednisolone treatment, approximately one-fourth of the measured PC species were sig-
nificantly decreased, whereby no effects based on acyl chain-length or saturation could be identified (Fig. 5a). 
These findings overlap with published data on reduced plasma PC levels after a single-dose of dexamethasone in 
humans51, which presumably result from GC-induced lipolysis.
In agreement with elevated plasma TG levels previously reported in humans and dogs with CS22,52, we 
observed significantly elevated levels of various TG species after long-term tetracosactide treatment (Fig. 6). These 
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increases were reflected in the total TG levels reported by clinical chemistry measurements (Fig. 1f). However, 
in contrast to the typically elevated total cholesterol levels in dogs and human with CS13,16,51, we did not observe 
any significant increases in serum total cholesterol and plasma CE levels (Figs 1h and 6). Three PUFA-containing 
CE species were also significantly decreased, which may reflect the same observation made for PUFA-containing 
acyl-glycerophospholipids.
The short-term prednisolone treatment led to a trend in reduced levels of many TG species (Fig. 6 and 
Supplementary Fig. S4). This observation matches previous findings in dogs and humans, where a single dose of 
dexamethasone resulted in decreased plasma TG levels51,53. However, our TG lipidomic results are not reflected 
by the total TG levels measured by clinical chemistry (Fig. 1e). This discrepancy may be explained by the overall 
small effects on total TGs and significant differences in the levels of specific TG species only. CE and total cho-
lesterol levels did not change, in agreement with previously reported effects of a single dose of dexamethasone in 
human and dogs51,53.
Our study revealed specific effects of both treatments on the plasma lipidome that were consistently observed 
across all individuals: (i) the increase in Hex1Cer after both short-term prednisolone and long-term tetracosac-
tide treatments; (ii) the decrease in PIs after short-term prednisolone treatment; and after long-term tetracosac-
tide, (iii) the decrease in ether-phospholipids, (iv) the increase of TGs and, (v) the decrease in the ratio of acyl 
phospholipids with 4 or more unsaturations compared with acyl phospholipids with a lower number of double 
bonds.
In summary, our data reveal wide-spread changes in the plasma lipidome—some for the first time—that 
occur in response to GC treatment, and highlight the similarities and differences between short- and long-term 
GC excess exposure in dogs. This study represents a first step toward a detailed characterisation of the influ-
ence of GCs on the lipid metabolome in dogs and other organisms. These data indicate that our dog model of 
tetracosactide-induced CS is a promising approach to study the effects of hypercortisolism on lipid metabolism in 
dogs. The relevance of our study can also be translated to human diseases, as many of the enzymes in lipid path-
ways that are regulated by GCs are dysregulated in chronic conditions of GC excess; as well as in e.g., metabolic 
syndrome and CS54. Our findings support the potential use of these plasma lipid classes as markers to monitor the 
effects of short- and long-term GC use. Finally, our results highlight that co-medication with a GC can be a sig-
nificant confounding factor when analysing the plasma lipidome of patients, such as in those with auto-immune 
diseases (e.g., rheumatoid arthritis and lupus erythematosus)1. Beyond the scope of the present study, the biolog-
ical role and significance of these findings will need to be evaluated in future investigations to provide deeper and 
novel insights of GC signalling and the impact of GCs on metabolism in health and disease.
Methods
Animals. Purpose-bred male and female Beagle dogs were used in both experiments. The dogs were kept 
in groups at the research unit of the Vetsuisse Faculty of the University of Zurich and fed a standard commer-
cial maintenance (pellet/kibble) diet (Josera, Adult Sensitive, Kleinheubach, Germany). The experimental 
group treated with short-term prednisolone included 8 dogs (5 male and 3 females, 8–58 months old, 12.7 to 
16.0 kg body weight). The long-term tetracosactide-treated group included 6 dogs (4 male and 2 female, 23 to 83 
months old, 12.2 to 18.9 kg body weight) (see Supplementary Table S1). The study was approved by the Cantonal 
Veterinary Office of Zurich, Switzerland (TVB 133/2013; 276/2014) and conducted in accordance with guidelines 
established by the Animal Welfare Act of Switzerland.
short-term prednisolone treatment. Eight Beagle dogs were treated with 50 mg prednisolone (Streuli 
Pharma AG, Uznach, Switzerland) orally twice daily for 3 consecutive days (prednisolone group). Blood samples 
were collected before (control) and at 12 h after the last prednisolone treatment.
Long-term tetracosactide treatment. Six Beagle dogs were infused subcutaneously (Alzet osmotic 
pump, Durect Corporation, Cupertino, CA, USA) for 25 weeks with tetracosactide (synthetic ACTH; Bachem 
AG, Bubendorf, Switzerland) (tetracosactide group). Every 4 weeks, new pumps were implanted subcutaneously 
into the dorsolateral neck under general anaesthesia to deliver increasing doses of tetracosactide. Dogs received 
a starting dose of 1.3–1.95 µg/kg/d tetracosactide, increasing the concentration to a final dose of 6–10 µg/kg/d. 
Blood samples were collected before (control) and at 25 weeks after treatment commenced.
The successful induction of hypercortisolism was tested with an ACTH stimulation test and a low-dose dex-
amethasone suppression test at 25 weeks after the start of treatment. For the ACTH stimulation test22, 5 μg/kg 
synthetic tetracosactide (Synacthen, Novartis Pharma Schweiz AG, Bern, Switzerland, Pharmacode: 6748610) 
was injected intravenously, and plasma cortisol measured at 0 and 1 h after injection. For the low-dose dexameth-
asone suppression (LDDS) test, 0.01 mg/kg dexamethasone (Dexadreson, MSD Animal Health GmbH, Luzern, 
Switzerland, ATCvet number: QH02AB02) was injected intravenously, and plasma cortisol measured at 0, 4, and 
8 h after injection.
Blood collection and processing. Blood samples were collected from the jugular vein after overnight 
fasting before (control) and at the end of the treatment (see above). For lipidomics analyses, blood was collected 
into lithium heparin tubes (Vacuette Greiner Bio-One, Frickenhausen, Germany) and centrifuged immediately 
after collection (1,862 g, 10 min, 4 °C). Obtained plasma was stored at −80 °C until analysis. For clinical chemistry 
analyses, serum was harvested after clot retraction at room temperature.
Clinical chemistry. All clinical blood serum chemistry parameters were determined at the Clinical 
Laboratory, Vetsuisse Faculty (University of Zurich) on a Cobas Integra 800 instrument (Roche Diagnostics 
AG, Rotkreuz, Switzerland). The clinical chemistry parameters included triglycerides, cholesterol, alanine ami-
notransferase (ALAT), alkaline phosphatase (ALP), lipase and other metabolites (Fig. 1 and Supplementary 
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Table S1). Serum cortisol concentrations were measured by a competitive immunoassay validated for dogs (DPC 
Immulite 1000, Siemens Schweiz AG, Zurich, Switzerland). The intra-assay coefficients of variation were 10.0% 
and 6.3% at cortisol levels of 2.7 and 18.9 µg/dL, respectively. The sensitivity of the assay was 0.2 µg/dL.
Quality control samples for lipidomic analyses. For the lipidomics analyses, Process Quality Control 
(PQC) samples were generated for each experimental group (prednisolone and tetracosactide, respectively) by 
pooling equal volumes of each plasma sample within an experimental group. Aliquots (10 µL) of corresponding 
pooled PQC samples were then tested alongside samples of each experimental group. Blank samples, which did 
not contain any plasma, were also prepared and tested (see “Lipid extraction”).
Lipid extraction. Plasma lipids were extracted using a modified version of the butanol/methanol extrac-
tion method55. Briefly, plasma samples were thawed on ice, and 10 µL of each sample (or PQC or control) was 
then transferred into a 2-mL Eppendorf tube (Eppendorf, Germany). Nothing was added to the tubes to be 
used as Blank samples. To prevent lipid oxidation, 1 µL of 2,6-di-tert-butyl-4-methylphenol (BHT, 10 mmol/L; 
Sigma-Aldrich; St Louis, MO, USA; B1378) in ethanol was added to each sample (including PQCs and Blanks). 
To this, 90 µL of 1-butanol:methanol (1:1, v/v) containing the internal standard lipids (Supplementary Table S8) 
was added. The samples were vortexed for 30 sec and sonicated in an ultrasound water bath at 20 °C for 30 min. 
After centrifugation (14,000 g, 10 min, 4 °C), 90 µL of supernatant were transferred into 1.5-mL tubes (Sarstedt 
Nümbrecht, Germany) and dried under a nitrogen stream at 37 °C. Samples were stored at −80 °C. Before use, 
samples were reconstituted in 90 µL of 1-butanol:methanol (1:1, v/v), sonicated for 10 min at room temperature, 
and centrifuged at 20,800 g, for 10 min at 4 °C. Then, 80 µL supernatant were transferred into autosampler vials 
with glass inserts (Agilent Technologies, Santa Clara, CA, USA) for LC-MS analysis.
LC-Ms analyses. Phospholipids, diacylglycerols, and cholesteryl esters were measured based on a published 
method56, with some modifications. Mobile phase A consisted of acetonitrile:water 4:6 (v:v) with 10 mmol/L 
ammonium formate (Sigma-Aldrich, 78314) and mobile phase B of acetonitrile:2-propanol 1:9 (v:v) with 
10 mmol/L ammonium formate. An Agilent Zorbax RRHD Eclipse Plus C18 (2.1 × 50 mm, 1.8 µm, 95 Å) 
reversed-phase column maintained at 40 °C was used as the stationary phase. The gradient was composed as 
follows: 20% B for 2 min, 20% to 60% B from 2 to 7 min, 60% to 100% B from 7 to 9 min, back to 20% B from 
9 min until the end (total runtime of 10.8 min). The flow rate was set to 0.4 mL/min and 2 µL sample was injected 
for analysis. The LC-MS system consisted of an Agilent 1290 infinity UHPLC pump and the Agilent 6460 triple 
quadrupole (QQQ) mass spectrometer. The ESI source parameters are detailed in Supplementary Table S9. All 
analyses were performed in dynamic MRM (multiple reaction monitoring) mode with unit resolution. Monitored 
transitions are listed in Supplementary Table S10.
Sphingolipids were measured using the same LC method described above. The injected sample volume was 
1 µL. An Agilent QQQ 6495 was used as a mass spectrometer, with distinct ESI source settings (see Supplementary 
Table S9) and MRM transition list (see Supplementary Table S11).
For triacylglycerols, the stationary phase consisted of an Agilent Zorbax Eclipse XDB-C18 Silica, 3 × 150 mm, 
1.8 μm, 80 Å column maintained at 25 °C. LC separation was performed isocratically for 25 min at a flow rate of 
128 μL/min with chloroform:methanol 1:1 (v:v) containing 2 mmol/L ammonium acetate (Sigma-Aldrich, 17843) 
as the mobile phase. The LC-MS system consisted of an Agilent 1100 HPLC pump and a Sciex 4000 QTrap mass 
spectrometer (SCIEX, Framingham, MA, USA) operated in single-ion monitoring (SIM) mode at unit reso-
lution to measure TG precursor ions (see Supplementary Table S12). The ESI source settings are described in 
Supplementary Table S9. The injected sample volume was 10 µL.
Sphingosine-1-phosphate (S1P) analysis was performed according to the method described by 
Narayanaswamy et al.35. To 50 µL of reconstituted lipid extract, 50 µL of 13C2D2–S1P d18:1 internal standard 
(20 ng/mL; Toronto Research Chemicals, Toronto, Canada) in 1-butanol:methanol (1:1, v/v) was added, and the 
sample was derivatized by the addition of 20 µL of TMS-diazomethane (2 mol/L in hexanes; Acros Organics, 
Thermo Fisher Scientific, New Jersey, USA) for 20 min at 25 °C and 700 rpm (Thermomixer, Eppendorf, 
Germany). The reaction was stopped by the addition of 1 µL of 100% acetic acid. Samples were centrifuged at 
20,800 g for 10 min at 7 °C, and supernatants transferred into autosampler vials for subsequent LC-MS analysis. 
The mobile phase A consisted of 1:1 (v/v) acetonitrile:25 mmol/L ammonium formate solution (in water, adjusted 
to pH 4.6 with formic acid), and the mobile phase B of 95:5 (v:v) acetonitrile: 25 mmol/L ammonium formate 
solution. Analytes were eluted with the following gradient: 99.9% B from 0 to 5 min; 40% B 5 to 5.5 min; 10% B 5.5 
to 6.6 min and 99.9% B 6.6 to 9.6 min (total run time 9.6 min). The flow rate was 0.4 mL/min. Samples (5 µL) were 
injected onto a Waters (Milford, USA) ACQUITY UPLC BEH HILIC (2.1 × 100 mm, 1.7 µm, 130 Å) analytical 
column maintained at 60 °C. The MS system consisted of an Agilent QQQ 6490. The ESI source parameters are 
indicated in Supplementary Table S9, and the monitored MRM transition list in Supplementary Table S13. Data 
acquisition was performed using Agilent MassHunter software (version B.06).
Ms data processing. The TG raw data was processed with Analyst (Version 1.6.2, SCIEX), and all other data 
from Agilent instruments with MassHunter QQQ Quantitative software (version B.08). The retention time and, if 
available, qualifier transitions were used to assign peaks to corresponding lipids. For sphingolipids, transitions of 
precursor ions with water loss were used as qualifiers. For S1P, the m/z 60 transitions were used as quantifiers and 
the interference from the S1P d18:1 M + 2 isotope was subtracted from S1P d18:057. For plasmalogen PE (PE-P), 
transitions with the fatty acid as product were used as quantifiers, and those with the head group as qualifiers. 
Plasmalogen PCs (PC-P), ether PCs (PC-O) and odd-chain fatty acid PCs were distinguished based on retention 
time56.
1 2Scientific RepoRts |          (2019) 9:6015  | https://doi.org/10.1038/s41598-019-42190-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
Normalised peak areas were calculated by dividing the peak areas of the analyte with the corresponding inter-
nal standard (ISTD; see Supplementary Table S14). Relative abundance was obtained by multiplying the normal-
ised peak areas with the molar concentration of the corresponding ISTD (see Supplementary Table S8). Lipid 
species with a median peak area in the PQC samples below 250 or less than 5 times of the Blank samples were 
excluded. Additionally, the coefficient of variation (CV) of the normalised peak area was calculated for each lipid 
species in the PQC samples of each experimental group. Species with a CV higher than 25% in any of the two 
groups were excluded from subsequent evaluation, except of Cer d18:1/18:0 and Hex1Cer d18:1/24:1, which had 
CVs of 27.8% and 30.1%, respectively, in the tetracosactide group, and 7.3% and 10.9% in the prednisolone group. 
These species were kept in the dataset to allow comparison between the two groups. The final filtered dataset 
included 262 lipid species quantified in all samples of both experimental groups (see Supplementary Table S2). 
The median %CVs of lipids species were 5.3% and 4.5% in the phospholipid/CE/DG, 12.1% and 10.9% in the 
sphingolipid, 8.5% and 13.1% in the S1P, and 18.1% and 18.4% in the TG panel analyses of the prednisolone and 
tetracosactide group, respectively. All calculations were performed using R58 (see Data Availability).
statistics and visualization. Statistical significance of changes in measured clinical chemistry parame-
ters, body weights and lipid abundances between dogs before and after treatment were determined by paired, 
two-tailed t-tests from log2-transformed values. FDR (false discovery rate)-adjusted P values were calculated 
using the Benjamini–Hochberg procedure. All calculations and figures were generated using R scripts using R58 
and following described R packages (see Data Availability). Heatmaps of the lipid abundances from samples 
before and after treatments (Fig. 2a,b) were generated using the heatmap.2 function of the gplots59 R package with 
Pearson’s distance and Ward clustering algorithms. The scales indicate autoscaled log2-fold changes. PCA plots 
were generated with the R packages FactoMineR60,61 and factoextra62 from scaled, centred log2-transformed lipid 
abundances (Fig. 2c,d) and log2-folds changes (Fig. 2e,f). The heatmaps of fold changes and FDR-adjusted P val-
ues (Figs 3 to 6) were generated using ComplexHeatmap63–65. Other plots were generated using ggplot266. Figures 
were scaled and further annotated in Adobe Illustrator CC (Adobe Systems, San Jose, CA).
Data Availability
The lipidomics dataset including the mass spectrometry raw data has been deposited to the Metabolomics Work-
bench67 (Project ID: PR000761) and is accessible via the DOI: 10.21228/M89Q3268. All R scripts used to generate 
the data and figures in this manuscript are available from Github (https://github.com/SLINGhub/Manuscript_
Sieber-Ruckstuhl_Burla_2019)69. The version of the Github repository at the time of writing this manuscript has 
been archived in Zenodo (DOI: 10.5281/zenodo.2581113)70.
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